Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Xenetic Biosciences, Inc. XBIO
$0.30
-$0.08 (-25.00%)
На 18:01, 12 мая 2023
+1 233.33%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
6096973.00000000
-
week52high
1.00
-
week52low
0.24
-
Revenue
1706925
-
P/E TTM
-1
-
Beta
2.77128000
-
EPS
-0.47000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 02 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 11 янв 2021 г. |
| Ladenburg Thalmann | Buy | 25 ноя 2020 г. | |
| Ladenburg Thalmann | Buy | 20 дек 2016 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| VINOGRADOV ALEXEY ANDREEVICH | A | 25000 | 25000 | 07 дек 2022 г. |
| Borisenko Grigory G. | A | 25000 | 25000 | 07 дек 2022 г. |
| Callaway James Eric | A | 25000 | 25000 | 07 дек 2022 г. |
| Dastoor Firdaus J. | A | 25000 | 25000 | 07 дек 2022 г. |
| Kornberg Roger D. | A | 25000 | 25000 | 07 дек 2022 г. |
| Logal Adam | A | 25000 | 25000 | 07 дек 2022 г. |
| EISENBERG JEFFREY F | A | 100000 | 100000 | 24 мар 2022 г. |
| Lockshin Curtis | A | 50000 | 50000 | 24 мар 2022 г. |
| PARSLOW JAMES F | A | 50000 | 50000 | 24 мар 2022 г. |
| Logal Adam | A | 25000 | 25000 | 07 дек 2021 г. |
Новостная лента
Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event
Accesswire
16 мар 2023 г. в 08:05
Live video webcast with moderated roundtable with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / March 16, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that it will participate in the Virtual Investor NETs in Cancer Spotlight Event on Wednesday, March 29, 2023 at 11:00 AM ET. For the roundtable discussion, Jeffrey F.
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
Accesswire
05 янв 2023 г. в 08:05
Live video webcast on Tuesday, January 17th at 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / January 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 10:00 AM ET. A live video webcast of the presentation will be available on the Events page in the Investors section of the Company's website (www.XeneticBio.com).
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Accesswire
07 сент 2022 г. в 08:05
FRAMINGHAM, MA / ACCESSWIRE / September 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the H.C.
VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences and Salarius Pharmaceuticals in push to develop cancer treatments
Proactive Investors
02 авг 2022 г. в 10:07
VolitionRx (NYSE-A:VNRX) Limited has inked a pair of research and development collaborations that will develop targeted, adoptive cell therapies to treat cancer and help advance a drug designed to treat solid and hematologic cancers. First off, the company will collaborate with Xenetic Biosciences (NASDAQ:XBIO) Inc to evaluate the potential combination of Volition's Nu.Q NETs Test and Xenetic's DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers.